Atrial Fibrillation Global Market Report 2025

Atrial fibrillation is a heart disorder characterized by an abnormality in the normal sequence of electrical impulses, leading to changes in the rate or rhythm at which the heart beats. This condition originates in the heart's upper chambers (atria) and can result in irregular heartbeats due to electrical impulses that are too fast, too slow, or erratic.

The main types of atrial fibrillation treatments can be categorized into surgical and non-surgical approaches. Surgical atrial fibrillation treatment involves administering an electrical shock on the outside of the chest to regulate the heartbeat, using paddles or patches. Various technologies, including radiofrequency, laser, cryotherapy, and others, are utilized for treatments, which encompass pharmacological, non-pharmacological, maze surgery, and electric cardioversion. These treatments are applied by various end-users, including hospitals, electrophysiology labs, and ambulatory surgical centers.

The atrial fibrillation market research report is one of a series of new reports from The Business Research Company that provides atrial fibrillation market statistics, including atrial fibrillation industry global market size, regional shares, competitors with an atrial fibrillation market share, detailed atrial fibrillation market segments, market trends and opportunities, and any further data you may need to thrive in the atrial fibrillation industry. This atrial fibrillation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The atrial fibrillation market size has grown rapidly in recent years. It will grow from $13.56 billion in 2024 to $15.14 billion in 2025 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to increasing awareness and screening programs, technological innovations in treatment, increasing healthcare expenditure, clinical research and drug development, genetic predisposition.

The atrial fibrillation market size is expected to see rapid growth in the next few years. It will grow to $24.93 billion in 2029 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to focus on stroke prevention, patient and physician education programs, global initiatives for cardiovascular health, increasing electrophysiology procedures, customization of treatment plans, government initiatives for cardiovascular disease prevention. Major trends in the forecast period include advancements in diagnostic technologies, rise in the incidence of atrial fibrillation, advancements in catheter ablation techniques, emergence of novel oral anticoagulants (NOACs), integration of wearable technologies for monitoring, expanding role of telemedicine in AF management, advancements in implantable devices.

The expansion of the atrial fibrillation market is poised to be driven by the escalating elderly population, particularly individuals aged 65 and above who face higher risks of falls due to factors like postural hypotension and mobility issues. The prevalence of conduction disturbances and age-related indicators on electrocardiograms before atrial fibrillation onset in this demographic further underscores this market growth. According to the World Health Organization's October 2022 report, the global population aged 60 and above is projected to reach 1.4 billion by 2030, marking a significant increase from 1 billion in 2020. By 2050, this age group is expected to double to 2.1 billion, with a substantial rise in the population aged 80 and older by 426 million compared to present numbers. Consequently, the burgeoning geriatric populace serves as a primary driver for the growth trajectory of the atrial fibrillation market.

The rise in cardiovascular diseases is anticipated to significantly boost the atrial fibrillation market. Cardiovascular diseases encompass a range of disorders affecting the heart and blood vessels, including conditions such as coronary artery disease, heart failure, and arrhythmias, which pose substantial risks to overall cardiovascular health. The increase in these conditions highlights the growing need for advanced diagnostic and treatment solutions, propelling the atrial fibrillation market as healthcare systems and industries respond to the challenges posed by the rising incidence of these diseases. For instance, a January 2022 article published by the American Heart Association, a US-based nonprofit organization focused on cardiovascular research, reported that approximately 19.1 million deaths worldwide were attributed to cardiovascular disease in 2022. Additionally, data from the Centers for Disease Control and Prevention, a US-based national public health agency, indicated that deaths from heart disease in the US rose from 659,041 in 2019 to 695,000 in 2021. Thus, the substantial burden of cardiovascular diseases globally is expected to drive growth in the atrial fibrillation market.

Key players within the atrial fibrillation market are actively introducing innovative products and solutions, such as patient-centric clinical decision support tools, to fortify their market position. Clinical decision support tools (CDST) are software or electronic systems designed to aid healthcare professionals in making informed and timely decisions regarding patient care. These tools are developed to assimilate pertinent clinical information from diverse sources. For instance, in August 2023, GE HealthCare launched CardioVisio, a patient-centered clinical decision support tool designed to assist physicians in evidence-based decision-making aligned with current atrial fibrillation guidelines. CardioVisio offers a comprehensive view of a patient's cardiac history, including past diagnoses, prescribed medications, interventions, and comorbidities. It enables cardiologists to streamline image interpretation and visualize longitudinal patient data critical for understanding disease progression and the patient's healthcare journey.

Leading enterprises within the atrial fibrillation market are leveraging cutting-edge advancements by introducing innovative products and solutions, such as a mapping catheter integrated with distinctive technology, aimed at consolidating their market standing. The mapping catheter constitutes a medical apparatus utilized in electrophysiology procedures, particularly within cardiac electrophysiology, to study the heart's electrical activity for diagnosing and managing various cardiac arrhythmias or irregular heart rhythms. In a notable development in July 2023, Biosense Webster Inc., a US-based company specializing in heart rhythm and heart disorder medical technology and diagnostics, unveiled the OPTRELL Mapping Catheter equipped with TRUEref technology. This tool facilitates high-definition electrophysiological mapping in complex cardiac arrhythmia cases like persistent atrial fibrillation (AFib), redo AFib ablation, atrial tachycardia, and ventricular tachycardia. Characterized by tiny electrodes arranged in a fixed array formation, the OPTRELL Mapping Catheter employs unique TRUEref technology to provide intelligent insights and high-resolution directional mapping. Clinicians benefit from a clearer comprehension of the arrhythmia's location, aiding in the development of more effective ablation strategies.

In an acquisition move in August 2022, Medtronic PLC, a US-based medical device corporation, acquired Affera, Inc. for an undisclosed sum. This strategic acquisition bolsters Medtronic's cardiac ablation portfolio by integrating Affera's cardiac mapping and navigation platform, a comprehensive amalgamation of diagnostic capabilities, focal pulsed field, and radiofrequency ablation solutions. Affera Inc., a US-based venture-backed medical device company operating within the atrial fibrillation market, contributes to Medtronic's expansion in this domain.

Major companies operating in the atrial fibrillation market are AtriCure Inc., Johnson & Johnson Private Limited, Abbott Laboratories, C.H. Boehringer Sohn AG & Co. KG, Biotronik Se & Co. Kg, Boston Scientific Corporation, Bristol-Myers Squibb Company, CardioFocus Inc., Sanofi S.A, Medtronic PLC, Biosense Webster Inc., MicroPort Scientific Corporation, Siemens AG, Acutus Medical Inc., AEGEA Medical Inc., Apama Medical Inc., Aria CV Inc., Armetheon Inc., BioSig Technologies Inc., Cardialen Inc., CardioRobotics Inc., CardioInsight Technologies Inc., Circa Scientific LLC, CorWave SA, EpiEP Inc., Farapulse Inc., Fibralign Corporation, Impulse Dynamics NV, JenaValve Technology Inc., Kardium Inc.

North America was the largest region in the atrial fibrillation market in 2024. Asia-Pacific is expected to be the fastest-growing region in the atrial fibrillation market report forecast period. The regions covered in the atrial fibrillation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the atrial fibrillation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The atrial fibrillation market includes revenues earned by entities from treatment for sinus bradycardia, premature atrial contractions (PACS), wandering atrial pacemakers, atrial tachycardia, multifocal atrial tachycardia, atrial flutter, and atrial fibrillation (Afib). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Atrial Fibrillation Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on atrial fibrillation market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for atrial fibrillation ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The atrial fibrillation market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Surgical; Non-Surgical
• 2) By Technology: Radiofrequency; Laser; Cryotherapy; Other Technologies
• 3) By Treatment Type: Pharmacological Treatment; Non-pharmacological Treatment; Maze Surgery; Electric Cardioversion
• 4) By End User: Hospitals; Electrophysiology Labs; Ambulatory Surgical Centers
• Subsegments:
• 1) By Surgical: Catheter Ablation; Maze Procedure; Hybrid Ablation Procedures
• 2) By Non-Surgical: Antiarrhythmic Drugs; Anticoagulants; Cardioversion Procedures; Device Implants
• Companies Mentioned: AtriCure Inc.; Johnson & Johnson Private Limited; Abbott Laboratories; C.H. Boehringer Sohn AG & Co. KG; Biotronik Se & Co. Kg
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.